Frans J Walther
Overview
Explore the profile of Frans J Walther including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
183
Citations
2115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Walther F, Zasadzinski J, Waring A
Expert Rev Respir Med
. 2024 Nov;
18(12):913-917.
PMID: 39534910
No abstract available.
2.
Walther F, Waring A
Am J Physiol Lung Cell Mol Physiol
. 2024 Oct;
327(6):L883-L889.
PMID: 39404798
Research on lung surfactant has exerted a great impact on newborn respiratory care and significantly improved survival and outcome of preterm infants with respiratory distress syndrome (RDS) due to surfactant...
3.
Walther F, Waring A
Biomedicines
. 2024 Jan;
12(1).
PMID: 38255268
Lung surfactant is a mixture of lipids and proteins and is essential for air breathing in mammals. The hydrophobic surfactant proteins B and C (SP-B and SP-C) assist in reducing...
4.
DiBlasi R, Crandall C, Engberg R, Bijlani K, Ledee D, Kajimoto M, et al.
Pharmaceutics
. 2023 Oct;
15(10).
PMID: 37896128
Aerosolized lung surfactant therapy during nasal continuous positive airway pressure (CPAP) support avoids intubation but is highly complex, with reported poor nebulizer efficiency and low pulmonary deposition. The study objective...
5.
Waring A, Jung G, Sharma S, Walther F
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37446012
Lung surfactant is a complex mixture of phospholipids and surfactant proteins that is produced in alveolar type 2 cells. It prevents lung collapse by reducing surface tension and is involved...
6.
Kurihara C, Sakurai R, Chuang T, Waring A, Walther F, Rehan V
Pulm Pharmacol Ther
. 2023 Mar;
80:102209.
PMID: 36907545
Introduction: Hyperoxia-induced lung injury is characterized by acute alveolar injury, disrupted epithelial-mesenchymal signaling, oxidative stress, and surfactant dysfunction, yet currently, there is no effective treatment. Although a combination of aerosolized...
7.
Chen X, Han D, Wang X, Huang X, Huang Z, Liu Y, et al.
Respir Res
. 2023 Feb;
24(1):39.
PMID: 36732726
Background: Ibuprofen is a nonsteroidal anti-inflammatory drug that is commonly used to stimulate closure of a patent ductus arteriosus (PDA) in very premature infants and may lead to aberrant neonatal...
8.
Waring A, Whitelegge J, Sharma S, Gordon L, Walther F
PLoS One
. 2022 Nov;
17(11):e0276787.
PMID: 36327300
The three-dimensional structure of the synthetic lung Surfactant Protein B Peptide Super Mini-B was determined using an integrative experimental approach, including mass spectrometry and isotope enhanced Fourier-transform infrared (FTIR) spectroscopy....
9.
Walther F, Waring A
Front Pediatr
. 2022 Jul;
10:923010.
PMID: 35783301
After shifting away from invasive mechanical ventilation and intratracheal instillation of surfactant toward non-invasive ventilation with nasal CPAP and less invasive surfactant administration in order to prevent bronchopulmonary dysplasia in...
10.
Walther F, Waring A, Otieno M, DiBlasi R
Respir Res
. 2022 Apr;
23(1):78.
PMID: 35379243
Background: Dry powder (DP) synthetic lung surfactant may be an effective means of noninvasive delivery of surfactant therapy to premature infants supported with nasal continuous positive airway pressure (nCPAP) in...